We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-20.00 | -1.02% | 1,934.00 | 1,925.00 | 1,926.00 | 1,956.00 | 1,919.00 | 1,955.00 | 145,039 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.88B | 192M | 0.8653 | 22.25 | 4.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
29/4/2022 07:31 | Market does not like it obviously.Still two more tranches of buybacks, one just started. At least more shares for the buybacks with the price fall. | montyhedge | |
29/4/2022 07:06 | All on track, generics growth 8% to 10% margins 24% to 25%.But market always want more. Strong cash generation continues. Forecast 2022 p.e 12.2. Hikma is always the Cinderella of the pharma sector on a low rating. | montyhedge | |
29/4/2022 06:39 | Robertball: No idea, both sound OK to me. It's all relative, it depends on what the market was expecting. But increased dividend, increased profits, and growth sound OK to me.... Its probably good (touchwood) | netcurtains | |
29/4/2022 06:21 | Injectables good. Generics poor?? | robertball | |
28/4/2022 11:38 | including MCRO? | phillis | |
28/4/2022 11:04 | Pound weak again, talk of $1.20 to the pounds, boost Hikma and dividend payments. All U.K. dollar earners I think would benefit. | montyhedge | |
27/4/2022 12:03 | Still cheaper the shareprice more they can buyback. | montyhedge | |
25/4/2022 18:48 | But would hit UK oil price and be inflationary | robertball | |
25/4/2022 16:56 | Standard Bank analyst said pound could go to $1.20 to pound, nice boost for Hikma if that happens. | montyhedge | |
22/4/2022 07:35 | The weak pound good for U.K. dollar earners, who report in dollars, bigger dividends when converted into sterling. | montyhedge | |
21/4/2022 15:33 | Where would this dog be without the buyback?? | blue59 | |
20/4/2022 08:25 | No I am MH, honest. Thanks for the info. | netcurtains | |
20/4/2022 08:18 | Custompharm takeover been given the green light in the US.Hikma growing, but market not interested it seems. | montyhedge | |
20/4/2022 08:07 | Odd response from mr market. Wonder who is selling - share price would be above 3000p by now | scepticalinvestor | |
18/4/2022 17:08 | Astra and Hikma the two shares to buy, to be on the same page as Astra that’s nice, lol. | montyhedge | |
14/4/2022 09:04 | I don't think so no rns. I just think investors think this safe boring 15 years of continuous dividend growth, is not exciting like say Astra or other pharma stocks. | montyhedge | |
13/4/2022 11:06 | Must be a substantial holder dumping | scepticalinvestor | |
13/4/2022 08:10 | Buybacks continues shareprice not moving at least they are buying back cheap, normally companies having buybacks pay top price. | montyhedge | |
10/4/2022 10:25 | British Bulls made this a buy on Friday: | netcurtains | |
08/4/2022 11:13 | Once again the Cinderella of the Pharma lagging behind, one day Cinders will join the ball. Forecast p.e 12.2. | montyhedge | |
08/4/2022 07:41 | Its working for GSK on most days (and also it appears to be working for PEARSON). I'm thinking SI, it probably will work for HIK too... Touchwood! | netcurtains | |
08/4/2022 07:18 | Share buyback not exactly working lol | scepticalinvestor | |
04/4/2022 11:31 | According to this article forecast forward p.e 12.2, if correct that is ridiculously cheap for a FTSE 100 pharma stock.https://www.fo | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions